US009636488B2

(12) **United States Patent**
Giesing

(10) **Patent No.: US 9,636,488 B2**
(45) **Date of Patent: May 2, 2017**

(54) **DRUG DELIVERY SYSTEMS AND METHODS FOR TREATMENT OF PROSTATE**

(71) Applicant: **TARIS Biomedical LLC**, Lexington, MA (US)

(72) Inventor: **Dennis Giesing**, Lee's Summit, MO (US)

(73) Assignee: **TARIS Biomedical LLC**, Lexington, MA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/628,874**

(22) Filed: **Feb. 23, 2015**

(65) **Prior Publication Data**

US 2015/0165177 A1 Jun. 18, 2015

Related U.S. Application Data

(63) Continuation of application No. PCT/US2013/057841, filed on Sep. 3, 2013.

(60) Provisional application No. 61/696,029, filed on Aug. 31, 2012.

(51) **Int. Cl.**

A61K 31/7068	(2006.01)
A61M 31/00	(2006.01)
A61K 9/00	(2006.01)
A61K 45/06	(2006.01)

(52) **U.S. Cl.**

CPC ***A61M 31/002*** (2013.01); ***A61K 9/0034*** (2013.01); ***A61K 31/7068*** (2013.01); ***A61K 45/06*** (2013.01); *A61M 2205/04* (2013.01); *A61M 2210/1085* (2013.01); *A61M 2210/166* (2013.01)

(58) **Field of Classification Search**

CPC A61K 31/7068; A61K 9/0034; A61M 31/002
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

6,171,298	B1	1/2001	Matsuura et al.
8,343,516	B2	1/2013	Daniel et al.
8,679,094	B2	3/2014	Cima et al.
8,690,840	B2	4/2014	Lee et al.
8,801,694	B2	8/2014	Lee et al.
9,017,312	B2	4/2015	Lee et al.
9,107,816	B2	8/2015	Lee et al.
2004/0260272	A1	12/2004	Friedman et al.
2009/0149833	A1	6/2009	Cima et al.
2010/0015200	A1	1/2010	McClain et al.
2010/0331770	A1	12/2010	Lee et al.
2011/0152839	A1	6/2011	Cima et al.
2012/0157917	A1	6/2012	Schroeder
2012/0203203	A1	8/2012	Lee et al.
2013/0324946	A1	12/2013	Tobias et al.
2014/0276636	A1	9/2014	Lee et al.
2015/0182516	A1	7/2015	Giesing

FOREIGN PATENT DOCUMENTS

EP	1 913 962	A1	4/2008
WO	2006/030431	A2	3/2006
WO	2009/139984	A2	11/2009
WO	2010/151893	A1	12/2010
WO	2011/031855	A2	3/2011
WO	2011/089604	A2	7/2011
WO	2012/048114	A1	4/2012
WO	2012/096985	A1	7/2012
WO	2014/036556	A2	3/2014
WO	2014/145638	A1	9/2014
WO	2015/026813	A1	2/2015

OTHER PUBLICATIONS

Morant et al., Ann. Oncol., 2000, 11, p. 183-188.*
Jantscheff et al., Prostate, 2009, 69, p. 1151-1163.*
Campodonico et al., "Intravesical Gemcitabine in Recurrent Superficial Bladder Carcinoma: Preliminary Results on Ablative Efficacy and Tolerability," Anticancer Research, 2005, 25:2381-2384.
Laufer et al., "Intravesical Gemcitabine Therapy for Superficial Transitional Cell Carcinoma of the Bladder: A Phase I and Pharmacokinetic Study," Journal of Clinical Oncology, 2003, 21(4):697-703.
Singapore Search Report and Written Opinion for SG Application No. 11201501483X mailed Jan. 5, 2016 (11 pages).
PCT International Search Report and Written Opinion for PCT Application No. PCT/US2013/057841 mailed Feb. 14, 2014 (18 pages).
PCT International Search Report and Written Opinion for PCT Application No. PCT/US2015/019262 mailed May 22, 2015 (15 pages).
Horinaga et al., "Enhanced Antitumor Effect of Coincident Intravesical Gemcitabine Plus BCG Therapy in an Orthotopic Bladder Cancer Model," Urology, 2010, 76(5):1267.e1-1267.e6.
Nativ et al., "Antineoplastic Effect of Gemcitabine in an Animal Model of Superficial Bladder Cancer," Urology, 2004, 54(4):845-848.
Shelley et al., "Intravesical Gemcitabine Therapy for Non-Muscle Invasive Bladder Cancer (NMIBC):A Systematic Review," BJU International, 2012, 496-505.
Xinwu et al., "Effect of Intravesical Instillation Capecitabine Combined with Oxaliplatin on the Recurrence of Bladder cancer," Anti-Tumor Pharmacy, 2011, 1(3)203-205.
Hendricksen et al., "Intravesical gemcitabine: an update of clinical results," Urology, 2006, 16:361-366.

* cited by examiner

Primary Examiner — Jonathan S Lau
(74) *Attorney, Agent, or Firm* — Eversheds Sutherland (US) LLP

(57) **ABSTRACT**

Methods, devices, and medicaments that include a drug are provided for use in the treatment of the prostate by locally administering the drug into the bladder of a patient to achieve a sustained concentration of the drug in urine in the bladder sufficient to produce a therapeutic concentration of the drug in the prostate. The drug may be delivered into the bladder from an intravesical drug delivery device inserted into the bladder, wherein the device continuously releases the drug into the urine in the bladder over an extended period of hours or days.

21 Claims, 11 Drawing Sheets